Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in methotrexate-inadequate response rheumatoid arthritis
2020-000658-83Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GLPG3970 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: Change from baseline in DAS28 (C-reactive protein) at Week 6. Started Oct 2020; status: completed.
02
Drugs
GLPG3970
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2020-000658-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000658-83.